HBM HEALTHCARE INVESTMENTS AG

(HBMN)
  Report
Delayed Swiss Exchange  -  11:31 2022-08-17 am EDT
269.50 CHF   +0.94%
08/16Key Figures 15.08.2022
EQ
08/11INSIDER SELL : Harmony Biosciences Holdings
MT
08/02Key Figures 31.07.2022
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shareholders' Meeting of HBM Healthcare Investments approved all proposals by the Board of Directors

06/10/2022 | 11:48am EDT

HBM Healthcare Investments AG / Key word(s): AGMEGM
Shareholders’ Meeting of HBM Healthcare Investments approved all proposals by the Board of Directors

10.06.2022 / 17:46


At today’s ordinary Shareholders’ Meeting of HBM Healthcare Investments Ltd the shareholders approved all proposals submitted by the Board of Directors. Based on the Federal Council's COVID 19 Ordinance 3, the meeting was held without the personal participation of shareholders. The independent proxy holder represented 34.45% of the outstanding shares.

The Chairman of the Board of Directors Hans Peter Hasler and the existing board members Dr Rudolf Lanz, Mario G. Giuliani,  Dr Stella X. Xu and Dr Elaine V. Jones were re-elected for a further one year term. The existing members of the Compensaiton Committee Mario G. Giuliani, Dr Stella X. Xu and Dr Elaine E. Jones were also re-elected for a further one year term.  Furthermore, the shareholders approved the proposed compensation to the Board of Directors and to the Management.

Further, the Shareholders’ Meeting approved a par value repayment of CHF 9.70 per share. The cash payment will be made on 1 September 2022. The registered shares with entitlement to the distribution will be traded for the last time on 29 August 2022 (from 30 August 2022 without, ex-date).

The Shareholders also agreed to a new share buy-back programme of up to a maximum of 10% of the shares outstanding, in order to cancel those shares as part of a capital reduction.

Contact
For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com.



End of Media Release


Language: English
Company: HBM Healthcare Investments AG
Bundesplatz 1
6300 Zug
Switzerland
Phone: +41438887171
Fax: +41438887172
E-mail: info@hbmhealthcare.com
Internet: https://www.hbmhealthcare.com
ISIN: CH0012627250
Valor: 1262725
Listed: SIX Swiss Exchange
EQS News ID: 1373407

 
End of News EQS News Service

1373407  10.06.2022 

fncls.ssp?fn=show_t_gif&application_id=1373407&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about HBM HEALTHCARE INVESTMENTS AG
08/16Key Figures 15.08.2022
EQ
08/11INSIDER SELL : Harmony Biosciences Holdings
MT
08/02Key Figures 31.07.2022
EQ
07/22HBM Healthcare Investments AG Reports Earnings Results for the First Quarter Ended June..
CI
07/22Swiss Healthcare Investor HBM Logs Fiscal Q1 Plunge in Net Result
MT
07/22HBM Healthcare Investments Quarterly Report June 2022
EQ
07/18Key Figures 15.07.2022
EQ
07/18HBM HEALTHCARE INVESTMENTS : Quarterly Report June 2022
PU
07/01Key Figures 30.06.2022
EQ
06/17Key Figures 15.06.2022
EQ
More news
Analyst Recommendations on HBM HEALTHCARE INVESTMENTS AG
More recommendations
Financials
Sales 2023 170 M 179 M 179 M
Net income 2023 122 M 128 M 128 M
Net cash 2023 35,0 M 36,8 M 36,8 M
P/E ratio 2023 15,2x
Yield 2023 3,63%
Capitalization 1 853 M 1 950 M 1 950 M
EV / Sales 2023 10,7x
EV / Sales 2024 7,40x
Nbr of Employees 700
Free-Float 82,7%
Chart HBM HEALTHCARE INVESTMENTS AG
Duration : Period :
HBM Healthcare Investments AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HBM HEALTHCARE INVESTMENTS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 267,00 CHF
Average target price 292,00 CHF
Spread / Average Target 9,36%
EPS Revisions
Managers and Directors
Andreas Wicki Chief Executive Officer
Erwin Troxler Chief Financial Officer
Hans-Peter Hasler Chairman
Rudolf Lanz Director
Mario Germano Giuliani Director